Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemborexant Treatment of Insomnia Linked to Epilepsy

Trial Profile

Lemborexant Treatment of Insomnia Linked to Epilepsy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lemborexant (Primary)
  • Indications Epilepsy; Sleep disorders
  • Focus Therapeutic Use
  • Acronyms L'ETOILE

Most Recent Events

  • 13 Feb 2025 Planned End Date changed from 18 Apr 2026 to 18 Apr 2027.
  • 13 Feb 2025 Planned primary completion date changed from 18 Apr 2025 to 18 Apr 2026.
  • 06 May 2024 Planned End Date changed from 8 Feb 2026 to 18 Apr 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top